139 related articles for article (PubMed ID: 6604863)
1. The interaction of immune serum globulin and immune globulin intravenous with complement.
Bing DH
Mol Immunol; 1983 Aug; 20(8):893-900. PubMed ID: 6604863
[TBL] [Abstract][Full Text] [Related]
2. Complement interaction with immune serum globulin and immune globulin intravenous.
Bing DH
Am J Med; 1984 Mar; 76(3A):19-24. PubMed ID: 6424450
[TBL] [Abstract][Full Text] [Related]
3. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity.
Berger M; Rosenkranz P; Brown CY
Clin Immunol Immunopathol; 1985 Feb; 34(2):227-36. PubMed ID: 4038476
[TBL] [Abstract][Full Text] [Related]
4. The IgG detected in the C1q solid-phase immune-complex assay is not always of immune-complex nature.
Hack CE; Belmer AJ
Clin Immunol Immunopathol; 1986 Jan; 38(1):120-8. PubMed ID: 3484437
[TBL] [Abstract][Full Text] [Related]
5. Effect of immune globulin intravenous on opsonization of bacteria by classic and alternative complement pathways in premature serum.
Shaio MF; Yang KD; Bohnsack JF; Hill HR
Pediatr Res; 1989 Jun; 25(6):634-40. PubMed ID: 2662129
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine.
Comis A; Easterbrook-Smith SB
FEBS Lett; 1986 Mar; 197(1-2):321-7. PubMed ID: 3485060
[TBL] [Abstract][Full Text] [Related]
7. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
Kilgallon W; Amlot PL; Williams BD
Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
[TBL] [Abstract][Full Text] [Related]
8. C1q and C3bi binding activities of the components of a plasmin-treated human immunoglobulin preparation.
Masuda K
Jpn J Med Sci Biol; 1983 Feb; 36(1):39-41. PubMed ID: 6223166
[TBL] [Abstract][Full Text] [Related]
9. Interaction of rabbit spermatozoa and serum complement components.
Suarez SS; Oliphant G
Biol Reprod; 1982 Sep; 27(2):473-83. PubMed ID: 6812656
[TBL] [Abstract][Full Text] [Related]
10. Three generations of immunoglobulin G preparations for clinical use.
McCue JP; Hein RH; Tenold R
Rev Infect Dis; 1986; 8 Suppl 4():S374-81. PubMed ID: 3092303
[TBL] [Abstract][Full Text] [Related]
11. Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A.
Römer J; Späth PJ; Skvaril F; Nydegger UE
Vox Sang; 1982 Feb; 42(2):74-80. PubMed ID: 6461133
[TBL] [Abstract][Full Text] [Related]
12. Interaction of bovine immunoglobulins with complement.
Sellei J
Comp Immunol Microbiol Infect Dis; 1987; 10(2):93-8. PubMed ID: 3497768
[TBL] [Abstract][Full Text] [Related]
13. Temperature-sensitive binding of solid phase C1q to aggregated human immunoglobulin G.
Gibbons JJ; Pohl DA; Tsai CC; Roodman ST
Biochim Biophys Acta; 1981 Sep; 670(2):146-9. PubMed ID: 6975125
[TBL] [Abstract][Full Text] [Related]
14. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.
Basta M; Fries LF; Frank MM
Blood; 1991 Aug; 78(3):700-2. PubMed ID: 1859883
[TBL] [Abstract][Full Text] [Related]
15. Proteins involved in the activation and control of the two pathways of human complement.
Reid KB
Biochem Soc Trans; 1983 Jan; 11(1):1-12. PubMed ID: 6298023
[No Abstract] [Full Text] [Related]
16. Dynamics of interaction between complement-fixing antibody/dsDNA immune complexes and erythrocytes. In vitro studies and potential general applications to clinical immune complex testing.
Taylor RP; Horgan C; Hooper M; Burge J
J Clin Invest; 1985 Jan; 75(1):102-11. PubMed ID: 3917462
[TBL] [Abstract][Full Text] [Related]
17. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
Wagner E; Platt JL; Frank MM
J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
[TBL] [Abstract][Full Text] [Related]
18. An analysis of the fluid phase C1q binding assay. The effect of endogenous C1q on the precipitation and detection of an immune complex model.
Jacobs RJ; Mocharla R
J Immunol Methods; 1988 May; 109(2):265-75. PubMed ID: 3258897
[TBL] [Abstract][Full Text] [Related]
19. Double immunofluorescence studies of immunoglobulins, complement components and their control proteins in patients with IgA nephropathy.
Tomino Y; Endoh M; Nomoto Y; Sakai H
Acta Pathol Jpn; 1982 Mar; 32(2):251-6. PubMed ID: 6211893
[TBL] [Abstract][Full Text] [Related]
20. Binding of complement components C1q, C3, C4 and C5 to a model immune complex in ELISA.
Larsson A; Sjöquist J
J Immunol Methods; 1989 Apr; 119(1):103-9. PubMed ID: 2785142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
